/images/ppid_59c68470-image-176829007156217345.webp)
/images/ppid_a911dc6a-image-176828753094111855.webp)
/images/ppid_a911dc6a-image-176828753099129504.webp)
/images/ppid_59c68470-image-176828755546658216.webp)
What is the story about?
Metropolis Healthcare Limited on Tuesday, January 13, said it is launching a Centre of Genomics, marking a major push to scale its capabilities in precision diagnostics, molecular testing and genomic research in India.
The diagnostics chain said the new centre will be backed by two CAP-accredited genomics laboratories in Mumbai and Delhi NCR, and will support high-impact clinical areas including oncology, reproductive health, neurology, transplant immunology and rare diseases.
Ameera Shah, Promoter and Executive Chairperson, Metropolis
Healthcare Limited said, through the Centre of Genomics, it brings together orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations.
"Supported by strong clinical stewardship from subject-matter experts, a multi-specialty Medical Advisory Board, and dedicated clinical support teams, this approach enables us to build one of India’s most comprehensive and clinically integrated genomic diagnostic platforms,” Shah said.
Metropolis Healthcare plans to expand its genomic portfolio to over 500 advanced tests over the next two to three years, up from more than 220 validated assays currently.
Dr. Kirti Chadha, Chief Scientific and Innovation Officer at Metropolis Healthcare said the Centre is aimed at translating advanced genomic science into actionable clinical insights across high-impact areas such as oncology, reproductive health, neurology, transplant immunology and rare diseases.
With the expansion plan in place, "the Centre of Genomics is benchmarked against leading global genomic laboratories in terms of breadth, quality, and clinical integration, while remaining closely aligned to India-specific disease patterns and care pathways,” Chadha added.
As part of the initiative, Metropolis has deployed Illumina’s NovaSeq X Series sequencing platform for research purposes, significantly enhancing throughput and accuracy in genomic analysis. The company said the platform strengthens its next-generation sequencing (NGS) infrastructure and supports advanced bioinformatics and clinical interpretation.
Suchita Dayanand, Country Head – India (Commercial), Illumina said, “As Illumina expands its presence in India, our mission is to make advanced sequencing technologies more accessible across the country.”
According to Metropolis, the centre will serve as a platform for AI-enabled analytics, continuous test development and deeper digital integration, while supporting pharmaceutical programs, clinical trials and global research partnerships.
Earlier this month, in its Q3 business update, the company said its consolidated revenue increased 26% year-on-year, driven by sustained momentum in preventive and wellness checkups under TruHealth, along with a strong increase in specialty testing volumes across both B2C and B2B channels.
The TruHealth Wellness and Specialty segments recorded 35% and 33% growth in the third quarter, respectively. The company's B2C revenues increased 18%, while its B2B revenue growth stood at 37%. Standalone revenue grew around 15% on account of increased patient and test volumes and a favourable shift in product mix and realisations.
Shares of Metropolis Health opened in green on Tuesday and were trading flat at ₹1,876.30 as of 11.49 am.
Also Read: NSE IPO Soon - How does the ₹5 lakh crore exchange stack up on various parameters
The diagnostics chain said the new centre will be backed by two CAP-accredited genomics laboratories in Mumbai and Delhi NCR, and will support high-impact clinical areas including oncology, reproductive health, neurology, transplant immunology and rare diseases.
Ameera Shah, Promoter and Executive Chairperson, Metropolis
Healthcare Limited said, through the Centre of Genomics, it brings together orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations.
"Supported by strong clinical stewardship from subject-matter experts, a multi-specialty Medical Advisory Board, and dedicated clinical support teams, this approach enables us to build one of India’s most comprehensive and clinically integrated genomic diagnostic platforms,” Shah said.
Metropolis Healthcare plans to expand its genomic portfolio to over 500 advanced tests over the next two to three years, up from more than 220 validated assays currently.
Dr. Kirti Chadha, Chief Scientific and Innovation Officer at Metropolis Healthcare said the Centre is aimed at translating advanced genomic science into actionable clinical insights across high-impact areas such as oncology, reproductive health, neurology, transplant immunology and rare diseases.
With the expansion plan in place, "the Centre of Genomics is benchmarked against leading global genomic laboratories in terms of breadth, quality, and clinical integration, while remaining closely aligned to India-specific disease patterns and care pathways,” Chadha added.
As part of the initiative, Metropolis has deployed Illumina’s NovaSeq X Series sequencing platform for research purposes, significantly enhancing throughput and accuracy in genomic analysis. The company said the platform strengthens its next-generation sequencing (NGS) infrastructure and supports advanced bioinformatics and clinical interpretation.
Suchita Dayanand, Country Head – India (Commercial), Illumina said, “As Illumina expands its presence in India, our mission is to make advanced sequencing technologies more accessible across the country.”
According to Metropolis, the centre will serve as a platform for AI-enabled analytics, continuous test development and deeper digital integration, while supporting pharmaceutical programs, clinical trials and global research partnerships.
Earlier this month, in its Q3 business update, the company said its consolidated revenue increased 26% year-on-year, driven by sustained momentum in preventive and wellness checkups under TruHealth, along with a strong increase in specialty testing volumes across both B2C and B2B channels.
The TruHealth Wellness and Specialty segments recorded 35% and 33% growth in the third quarter, respectively. The company's B2C revenues increased 18%, while its B2B revenue growth stood at 37%. Standalone revenue grew around 15% on account of increased patient and test volumes and a favourable shift in product mix and realisations.
Shares of Metropolis Health opened in green on Tuesday and were trading flat at ₹1,876.30 as of 11.49 am.
Also Read: NSE IPO Soon - How does the ₹5 lakh crore exchange stack up on various parameters
/images/ppid_a911dc6a-image-176828952665629431.webp)
